Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-30
2011-08-30
Fetterolf, Brandon (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254010, C514S326000, C514S422000, C544S141000, C544S372000, C546S208000, C548S523000
Reexamination Certificate
active
08008296
ABSTRACT:
The present invention discloses novel compounds of Formula I or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. (Formula I).
REFERENCES:
patent: WO 02/076925 (2002-10-01), None
patent: WO 03/064411 (2003-08-01), None
patent: WO 2004/037251 (2004-05-01), None
patent: WO 2005/097740 (2005-10-01), None
patent: WO 2006/011042 (2006-02-01), None
Beavers Lisa Selsam
Finley Don Richard
Gadski Robert Alan
Hipskind Philip Arthur
Hornback William Joseph
Eli Lilly and Company
Fetterolf Brandon
Pagonakis Anna
Wood Dan L.
LandOfFree
Histamine H3 receptor agents, preparation and therapeutic uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Histamine H3 receptor agents, preparation and therapeutic uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Histamine H3 receptor agents, preparation and therapeutic uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2675899